Estimation of SARS-CoV-2 Viral Dynamics Parameters in Favipiravir-Treated Cynomolgus Macaques: Comparison of Individual and Group Average Model Fitting.
- 1Department of Physics & Astronomy, Texas Christian University, Fort Worth, TX 76129, USA.
Abstract
Favipiravir, an antiviral that inhibits viral RNA-dependent RNA polymerase, has demonstrated promise as a therapeutic for RNA viral infections such as SARS-CoV-2. Mathematical modeling of viral kinetics provides a tool for analyzing the progression of viral infections and the action of antiviral drugs. In the present investigation, the viral kinetics of SARS-CoV-2 infection in cynomolgus macaques treated with the antiviral drug favipiravir were analyzed using a target-cell-limited mathematical model of viral infection. The model parameters were estimated by fitting the model independently to each of the 30 individual animals across four treatment groups (untreated control, 100 mg/kg, 150 mg/kg, and 180 mg/kg). Bootstrap resampling was applied to quantify the parameter uncertainty, and Mann-Whitney U tests were used to compare the group-level parameter estimates between the control and each treated group. Despite broad trends in several parameters, no statistically significant differences were detected between the control and any favipiravir-dose group. We also fit the model to the group-averaged viral titer curves, which led to statistically significant differences in some of the parameters. These results highlight the danger in using averaged viral titers when there is substantial inter-animal variability in individual viral kinetics data, and they suggest that larger cohorts may be required to detect drug effects with statistical confidence at the individual animal level.
Related
- Power coupling and plasma parameters of low-pressure microwave argon discharges in capillaries: comparison between surfatron and striplastron launchers
- Implausible 100-400 m Performance Times and Inadequate Testing Distances Compromise the Estimation and Interpretation of Critical Velocity. Comment on Amara et al. Relationships Between Dry-Land Load-Velocity Parameters and In-Water Bioenergetic Performance in Competitive Swimmers. Sports 2026, 14, 11.
- Team sport as a potential context for interpersonal emotion regulation in early adolescence: a quasi-experimental comparison with individual exercise
- Combined cold atmospheric plasma and photobiomodulation is associated with improved early macroscopic and ultrasonographic wound-healing parameters after unilateral mastectomy in female dogs: an exploratory randomized intra-individual controlled clinical study.
- Indirect comparison of reconstructed individual patient data from KEYNOTE-905/EV-303 and PURE-01: complementary analyses for interpreting event-free survival in muscle-invasive bladder cancer.
BibTeX
@article{shetty2026estimation,
title = {{Estimation of SARS-CoV-2 Viral Dynamics Parameters in Favipiravir-Treated Cynomolgus Macaques: Comparison of Individual and Group Average Model Fitting.}},
author = {Aarush Shetty and Hana M Dobrovolny},
journal = {Pathogens (Basel, Switzerland)},
year = {2026},
month = sep,
doi = {10.3390/pathogens15101007},
url = {https://europepmc.org/article/MED/42931159},
note = {CC BY},
}
RIS
TY - JOUR
TI - Estimation of SARS-CoV-2 Viral Dynamics Parameters in Favipiravir-Treated Cynomolgus Macaques: Comparison of Individual and Group Average Model Fitting.
AU - Aarush Shetty
AU - Hana M Dobrovolny
PY - 2026
DA - 2026/09/23
JO - Pathogens (Basel, Switzerland)
DO - 10.3390/pathogens15101007
UR - https://europepmc.org/article/MED/42931159
AB - Favipiravir, an antiviral that inhibits viral RNA-dependent RNA polymerase, has demonstrated promise as a therapeutic for RNA viral infections such as SARS-CoV-2. Mathematical modeling of viral kinetics provides a tool for analyzing the progression of viral infections and the action of antiviral drugs. In the present investigation, the viral kinetics of SARS-CoV-2 infection in cynomolgus macaques treated with the antiviral drug favipiravir were analyzed using a target-cell-limited mathematical model of viral infection. The model parameters were estimated by fitting the model independently to each of the 30 individual animals across four treatment groups (untreated control, 100 mg/kg, 150 mg/kg, and 180 mg/kg). Bootstrap resampling was applied to quantify the parameter uncertainty, and Mann-Whitney U tests were used to compare the group-level parameter estimates between the control and each treated group. Despite broad trends in several parameters, no statistically significant differences were detected between the control and any favipiravir-dose group. We also fit the model to the group-averaged viral titer curves, which led to statistically significant differences in some of the parameters. These results highlight the danger in using averaged viral titers when there is substantial inter-animal variability in individual viral kinetics data, and they suggest that larger cohorts may be required to detect drug effects with statistical confidence at the individual animal level.
SN - 2076-0817
ER -